David Tougeron, MD, PhD, Poitiers University Hospital, Poitiers, France, provides an overview of the current status and future directions of treating MSI-high colorectal cancer (CRC). MSI-high CRC is currently treated with pembrolizumab demonstrating significant efficacy, however, approximately 20% of patients experience primary resistance and approximately 30% experience secondary resistance. Dr Tougeron therefore emphasizes the identification and use of biomarkers to predict efficacy of pembrolizumab, such as liver metastasis which indicates patients will have a poorer response to pembrolizumab. Additionally, ongoing studies are investigating the predictive value of T-cell infiltration in the tumor. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.